Stocks Health care ISCO
OTC · Health careInternational Stem Cell CORP (ISCO)
International Stem Cell CORP brought in $9.5M of revenue over the twelve months to June 30, 2026, up 3.4% from a year earlier. It posted a net loss of $582K. In fiscal 2025 capital spending exceeded operating cash flow by $35K. At June 30, 2026 it held $1.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch ISCO in 60 secondsWhat International Stem Cell CORP does
International Stem Cell CORP is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ISCO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.1M | -$418K | -$0.05 | -$35K |
| 2024 | $9.1M | -$209K | -$0.03 | -$153K |
| 2023 | $7.8M | -$131K | -$0.02 | $849K |
| 2022 | $8.2M | -$331K | -$0.04 | $331K |
| 2021 | $7.2M | -$899K | -$0.11 | -$1.3M |
| 2020 | $7.1M | -$2.7M | -$0.36 | -$369K |
Full financial statements: income, balance sheet and cash flow
Where ISCO ranks in Health care
Latest SEC filings
What International Stem Cell CORP has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.3% to $2.7M versus the same quarter last year; diluted EPS -$0.01 versus $0.01.
- August 4, 2026Form DEF 14C filing DEF 14C
- July 24, 2026Form PRE 14C filing PRE 14C
- July 16, 2026
- June 12, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 8.7% to $2.3M versus the same quarter last year; diluted EPS -$0.03 versus -$0.03.
- April 29, 2026
- April 29, 2026Proxy statement DEF 14A
- March 30, 2026Annual report 10-K · period to December 31, 2025Revenue was flat at $9.1M versus the prior year; diluted EPS -$0.05 versus -$0.03.
Insider trades
What the people running International Stem Cell CORP did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $10.5K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Maier Paul VDirector | Soldindirect | 32,802 | $10.5K |
Questions about ISCO
What does International Stem Cell CORP do?
International Stem Cell CORP is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ISCO.
Is International Stem Cell CORP profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $582K on revenue of $9.5M.
How much revenue does International Stem Cell CORP make?
Over the twelve months to June 30, 2026 International Stem Cell CORP reported revenue of $9.5M. That is 3.4% more than a year earlier.
When did International Stem Cell CORP last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
Similar companies
Compare ISCO with
Follow ISCO
Get an email when International Stem Cell CORP files with the SEC: results, executive changes, material agreements and annual reports.
Follow ISCO: get an email when it filesWhere the numbers come from
Financial figures are the values International Stem Cell CORP tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.